Products Categories
    Product Certification&
    Enterprise Certification

  • Mr.Xie
    Tel: +86-592-5853819

  • Ms.Serein Yan
    Region Sales Manager
    Tel: +86 0592 5887162

  • Ms.Coco Lv
    Region Sales Manager
    Tel: 0086-592-5881075

  • Ms.Penny Pan
    Region Sales Manager
    Tel: 0086-592-5881087

  • Ms.Shirley Shi
    Region Sales Manager
    Tel: +8613666090822

  • Ms.Denise Lai
    Region Sales Manager
    Tel: 0086-592-5887167

  • Mr.Duncan Deng
    Region Sales Manager
    Tel: +8617750663255

  • Ms.Susie Yan
    Region Sales Manager
    Tel: +8618060975837

  • Ms.Annette Wang
    Region Sales Manager
    Tel: +8615882299465

  • Mobile:+86 13806035118
  • Tel:+86-592-5853819
  • Fax:+86-592-5854960
  • URL:http://www.china-sinoway.com
  • Province/state:fujian
  • City:Xiamen
  • Street:16/F,Huicheng Comm,Complex,No839 XiaHe Rd, Xiamen,China
  • MaxCard:
Home > Products >  factory supply DMF Apixaban

factory supply DMF Apixaban CAS NO.124750-99-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,Other
  • Product Details

Keywords

  • Apixaban
  • Rivaroxaban
  • 124750-99-8

Quick Details

  • ProName: factory supply DMF Apixaban
  • CasNo: 124750-99-8
  • Molecular Formula: C22H23ClKN6O
  • Appearance: White crystallization
  • Application: oral anticoagulant drug
  • DeliveryTime: in two weeks
  • PackAge: 25kg/drum
  • Port: SHANGHAI BEIJING
  • ProductionCapacity: 10 Metric Ton/Day
  • Purity: USP/EP/BP
  • Storage: room temperature
  • Transportation: AIR SEA TRAIN
  • LimitNum: 1 Kilogram

Superiority

We are very compeitive on Apixaban.Our mfr is with DMF document. 

Product Name: Apixaban
CAS: 503612-47-3
MF: C25H25N5O4
MW: 459.5
EINECS: 639-684-6
Product Categories: Inhibitors;Inhibitor;API
 

Details

Mechanisms of Action Apixaban is an oral selective activated Xa factor inhibitor and can prevent thrombin generation and thrombosis.
Clinical Research Apixaban is the third new oral anticoagulant to go on sale, following dabigatran and rivaroxaban, and it has already been approved in Europe for preventing venous thromboembolism in patients undergoing elective hip or knee replacement surgery. Out of these three oral anticoagulants approved in Europe, compared to the current standard preventative treatment against venous thromboembolism, enoxaparin, rivaroxaban excelled in the record experiment, and apixaban excelled in the advance experiment. Rivaroxaban’s curative effects were slightly superior, but it caused more severe bleeding than apixaban. Researchers attributed these differences to medication time, as rivaroxaban was taken 6-8 hours after surgery in the record experiment, while apixaban was used 18 hours after surgery in the advance experiment. These drugs have better curative effect when used closer to time of surgery, but also have an increased bleeding risk. Clinical research showed that compared to a daily subdermal injection of 40mg enoxaparin, 2 oral 2.5mg dosages of apixaban had better preventative effects against venous thromboembolism following hip or knee replacement surgery and did not increase bleeding risk.

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog